DK1026237T3 - Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40 - Google Patents

Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40

Info

Publication number
DK1026237T3
DK1026237T3 DK00104460T DK00104460T DK1026237T3 DK 1026237 T3 DK1026237 T3 DK 1026237T3 DK 00104460 T DK00104460 T DK 00104460T DK 00104460 T DK00104460 T DK 00104460T DK 1026237 T3 DK1026237 T3 DK 1026237T3
Authority
DK
Denmark
Prior art keywords
kinases
tau
inhibitor
protein kinase
neurofilament protein
Prior art date
Application number
DK00104460T
Other languages
English (en)
Inventor
Vernon M Ingram
Hanno M Roder
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK1026237T3 publication Critical patent/DK1026237T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00104460T 1991-08-09 1992-07-10 Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40 DK1026237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74288091A 1991-08-09 1991-08-09
EP92915162A EP0667898B1 (en) 1991-08-09 1992-07-10 Uses of the tau/neurofilament protein kinase pk40

Publications (1)

Publication Number Publication Date
DK1026237T3 true DK1026237T3 (da) 2004-07-19

Family

ID=24986618

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92915162T DK0667898T3 (da) 1991-08-09 1992-07-10 Anvendelser af TAU/neurofilamentproteinkinasen PK40
DK00104460T DK1026237T3 (da) 1991-08-09 1992-07-10 Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK92915162T DK0667898T3 (da) 1991-08-09 1992-07-10 Anvendelser af TAU/neurofilamentproteinkinasen PK40

Country Status (9)

Country Link
EP (2) EP1026237B1 (da)
JP (1) JPH06510427A (da)
AT (2) ATE206755T1 (da)
AU (1) AU675410B2 (da)
CA (1) CA2115151C (da)
DE (2) DE69233330T2 (da)
DK (2) DK0667898T3 (da)
ES (2) ES2165358T3 (da)
WO (1) WO1993003148A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398176T1 (de) * 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
CN1461366A (zh) * 2000-07-07 2003-12-10 美利肯公司 具有耐久拒水和易去污性的纺织基材及其制法
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
RU2639537C2 (ru) * 2011-10-07 2017-12-21 Ац Иммуне С.А. Фосфоспецифичные антитела, распознающие тау

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920703068A (ko) * 1989-09-15 1992-12-17 폴 레이킨드 신경변성 질환의 치료방법
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
WO1993003177A1 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease

Also Published As

Publication number Publication date
ES2165358T3 (es) 2002-03-16
JPH06510427A (ja) 1994-11-24
AU2324092A (en) 1993-03-02
CA2115151C (en) 2005-05-17
ATE262584T1 (de) 2004-04-15
DE69232121D1 (de) 2001-11-15
DK0667898T3 (da) 2002-02-04
DE69233330D1 (de) 2004-04-29
EP0667898B1 (en) 2001-10-10
EP0667898A1 (en) 1995-08-23
DE69232121T2 (de) 2002-06-20
ATE206755T1 (de) 2001-10-15
EP1026237B1 (en) 2004-03-24
EP1026237A3 (en) 2001-03-28
ES2216745T3 (es) 2004-11-01
EP1026237A2 (en) 2000-08-09
WO1993003148A2 (en) 1993-02-18
CA2115151A1 (en) 1993-02-18
AU675410B2 (en) 1997-02-06
DE69233330T2 (de) 2005-03-10
WO1993003148A3 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
ATE299145T1 (de) Neues multimerisierendes reagenz
EA199700061A1 (ru) Способ получения силденафила
DE10299011I1 (de) Interleukin-1-Inhibitoren
IE892272L (en) Novel fused heterocyclic compounds
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
DE69731285D1 (de) Langwellig fluorezierende proteine
ATE236886T1 (de) 2,4-dioxo-imidazolidin-derivate
DK0788356T3 (da) Fremgangsmåde og præparater til hæmning af proteinkinaser
NO944406D0 (no) Nye 7 se inhibitorer
DK0619806T3 (da) Fremstilling af substituerede piperidiner
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
DK1026237T3 (da) Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
DE69625910D1 (de) Penamsulfone als beta-laktamase inhibitoren
DK192890A (da) 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
DK133793D0 (da) Fremgangsmaade til dehydrogenering af carbonhydrider
DK0519512T3 (da) Mikrobiologisk fremgangsmåde til fremstilling af 5-hydroxypyrazincarboxylsyre
DK0689440T3 (da) Anvendelse af triazinforbindelser som anxiolytikum
DK509085A (da) Fremgangsmaade til stabilisering af bacampicillinhydroklorid
FI920926A7 (fi) Menetelmä korkea-alkalisten proteaasien stabiilisuuden parantamiseksi
GR1001386B (el) Ετεροκυκλικές ενώσεις.
DK499686A (da) Heterocykliske forbindelser, fremgangsmaade til fremstilling af samme samt anvendelse af disse forbindelser
IT8934058V0 (it) Insieme ammortizzato per bicicletta (kit).